3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Mantle-Cell
5
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Lymphoma, B-Cell
1
Leukemia, Hairy Cell
1
Interventions
Rituximab
12
Tacrolimus
11
Peripheral Blood Stem Cell Transplantation
10
Mycophenolic Acid
9
fludarabine phosphate
8
Cyclophosphamide
8
Whole-Body Irradiation
6
Methotrexate
5
Cyclosporine
5
Antilymphocyte Serum
5
Vemurafenib
4
Methylprednisolone
4
Cladribine
4
Busulfan
4
merphos
3
Therapeutics
3
Radiotherapy
3
Alemtuzumab
3
obinutuzumab
2
ibrutinib
2
fludarabine
2
binimetinib
2
aldesleukin
2
Transplantation
2
Specimen Handling
2
Prednisone
2
Melphalan
2
Lenalidomide
2
Interferon-alpha
2
Filgrastim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Leukemia, Hairy Cell
×
brexucabtagene autoleucel
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts